Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

James Vasselli; Paul de Souza; Sophia Frentzas; Andrew Weickhardt; Timothy Wyant; Jenny Tang; Aron Knickerbocker; Inbar Amit; Yanay Ofran

Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

James Vasselli, Paul de Souza, Sophia Frentzas, Andrew Weickhardt, Timothy Wyant, Jenny Tang, Aron Knickerbocker, Inbar Amit, Yanay Ofran

The Mina and Everard Goodman Faculty of Life Sciences - at Bar-Ilan University

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Number of pages	1
State	Published - 3 Jun 2022
Event	American Society of Clinical Oncology (ASCO) Annual Meeting - Duration: 3 Jun 2022 → 7 Jun 2022

Conference

Conference	American Society of Clinical Oncology (ASCO) Annual Meeting
Period	3/06/22 → 7/06/22

Cite this

Vasselli, J., Souza, P. D., Frentzas, S., Weickhardt, A., Wyant, T., Tang, J., Knickerbocker, A., Amit, I., & Ofran, Y. (2022). Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors. Abstract from American Society of Clinical Oncology (ASCO) Annual Meeting.

@conference{736ddbb205364dbf84b71a91864a1f2d,

title = "Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors",

author = "James Vasselli and Souza, {Paul de} and Sophia Frentzas and Andrew Weickhardt and Timothy Wyant and Jenny Tang and Aron Knickerbocker and Inbar Amit and Yanay Ofran",

year = "2022",

month = jun,

day = "3",

language = "אנגלית",

note = " American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 03-06-2022 Through 07-06-2022",

}

Vasselli, J, Souza, PD, Frentzas, S, Weickhardt, A, Wyant, T, Tang, J, Knickerbocker, A, Amit, I & Ofran, Y 2022, 'Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors', American Society of Clinical Oncology (ASCO) Annual Meeting, 3/06/22 - 7/06/22.

Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors. / Vasselli, James; Souza, Paul de; Frentzas, Sophia et al.
2022. Abstract from American Society of Clinical Oncology (ASCO) Annual Meeting.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

AU - Vasselli, James

AU - Souza, Paul de

AU - Frentzas, Sophia

AU - Weickhardt, Andrew

AU - Wyant, Timothy

AU - Tang, Jenny

AU - Knickerbocker, Aron

AU - Amit, Inbar

AU - Ofran, Yanay

PY - 2022/6/3

Y1 - 2022/6/3

UR - https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xtRXLdkAAAAJ&sortby=pubdate&citation_for_view=xtRXLdkAAAAJ%3AhzvVvKpMvx4C&inst=1200643855431153338

M3 - ???researchoutput.researchoutputtypes.contributiontoconference.abstract???

T2 - American Society of Clinical Oncology (ASCO) Annual Meeting

Y2 - 3 June 2022 through 7 June 2022

ER -

Vasselli J, Souza PD, Frentzas S, Weickhardt A, Wyant T, Tang J et al.. Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors. 2022. Abstract from American Society of Clinical Oncology (ASCO) Annual Meeting.

Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

Conference

Other files and links

Cite this